Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Guardant Health Inc (GH)

Guardant Health Inc (GH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,201,431
  • Shares Outstanding, K 131,170
  • Annual Sales, $ 982,020 K
  • Annual Income, $ -416,280 K
  • EBIT $ -437 M
  • EBITDA $ -403 M
  • 60-Month Beta 1.67
  • Price/Sales 12.46
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 57.59% (+1.15%)
  • Historical Volatility 50.02%
  • IV Percentile 27%
  • IV Rank 18.05%
  • IV High 103.43% on 04/04/25
  • IV Low 47.50% on 08/13/25
  • Expected Move (DTE 15) 7.99 (8.63%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 535
  • Volume Avg (30-Day) 895
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 18,093
  • Open Int (30-Day) 20,392
  • Expected Range 84.59 to 100.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.75
  • Number of Estimates 4
  • High Estimate -0.68
  • Low Estimate -0.84
  • Prior Year -0.77
  • Growth Rate Est. (year over year) +2.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
88.21 +4.95%
on 03/03/26
113.78 -18.63%
on 02/20/26
-5.78 (-5.88%)
since 02/05/26
3-Month
88.21 +4.95%
on 03/03/26
120.74 -23.32%
on 01/22/26
-9.44 (-9.25%)
since 12/05/25
52-Week
34.88 +165.42%
on 03/10/25
120.74 -23.32%
on 01/22/26
+49.92 (+117.02%)
since 03/05/25

Most Recent Stories

More News
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America

Shield Across America mobile screening tour launches during Colorectal Cancer Awareness Month to address nation’s dangerously low screening rates by bringing Shield blood test directly to Americans ...

GH : 92.58 (-0.47%)
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened

1 in 3 eligible Americans avoid colorectal cancer (CRC) screenings because traditional methods are viewed as unpleasant and inconvenient Guardant's FDA-approved...

GH : 92.58 (-0.47%)
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know

Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know

SOLV : 70.78 (+0.54%)
GH : 92.58 (-0.47%)
ALHC : 18.57 (-1.64%)
ANIP : 75.60 (-1.22%)
CLOV : 2.07 (-4.17%)
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 23, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting...

GH : 92.58 (-0.47%)
Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know

Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know

GH : 92.58 (-0.47%)
OMCL : 42.25 (+1.73%)
PACB : 1.5200 (-2.56%)
ALGN : 175.60 (-3.60%)
QDEL : 21.41 (+1.04%)
Stocks Rally After Supreme Court Rejects President Trumps Tariffs

The S&P 500 Index ($SPX ) (SPY ) today is up +0.43%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.33%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.60%. U.S. equities climbed on Friday...

APO : 111.24 (+1.32%)
ARES : 117.04 (+0.71%)
GH : 92.58 (-0.47%)
OWL : 10.42 (+0.77%)
$SPX : 6,830.71 (-0.56%)
AKAM : 101.00 (-1.92%)
LYV : 159.78 (+0.72%)
TPG : 44.96 (-1.34%)
RNG : 39.67 (+1.28%)
$IUXX : 25,020.41 (-0.29%)
ZNM26 : 112-140 (+0.11%)
QQQ : 608.91 (-0.30%)
Guardant Health: Q4 Earnings Snapshot

Guardant Health: Q4 Earnings Snapshot

GH : 92.58 (-0.47%)
Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales

Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales

GH : 92.58 (-0.47%)
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

Fourth quarter 2025 revenue growth of 39% broadly driven by strong performance across Oncology and Screening Expects full year 2026 total revenue to grow in the range...

GH : 92.58 (-0.47%)
Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow

Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow

GH : 92.58 (-0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption,...

See More

Key Turning Points

3rd Resistance Point 101.83
2nd Resistance Point 99.18
1st Resistance Point 95.88
Last Price 92.58
1st Support Level 89.92
2nd Support Level 87.27
3rd Support Level 83.97

See More

52-Week High 120.74
Last Price 92.58
Fibonacci 61.8% 87.94
Fibonacci 50% 77.81
Fibonacci 38.2% 67.68
52-Week Low 34.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar